

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Osbakken et al.

Serial Number: 09/942,959

Filing Date: August 31, 2001

Title: Aerosolized Anti-Infectives, Anti-Inflammatories, and Decongestants for the Treatment of Sinusitis

Group Art Unit: 1614

Examiner: Donna Jagoe

CONFIRMATION NO: 7962Certificate of Electronic Filing

I hereby certify that the attached Supplemental Information Disclosure Statement and all marked attachments are being deposited by Electronic Filing on December 15, 2006 by using the EFS - Web patent filing system and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: Ann Lygas
Ann LygasDate: December 15, 2006

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.97

Sir:

Applicant hereby submits a Supplemental Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicant respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant further requests that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A. 37 CFR §1.97(b). This Information Disclosure Statement should be considered by the Office because:

(1) It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);

-- OR --

(2) It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;

-- OR --

(3) It is being filed before the mailing of a first Office action on the merits;

-- OR --

(4) It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.

B. 37 CFR §1.97(c). Although this Information Disclosure Statement is being filed after the period specified in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final office action under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise closes prosecution on the merits, this Information Disclosure Statement should be considered because it is accompanied by one of:

a statement as specified in §1.97(e) provided concurrently herewith;

-- OR --

a fee of \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.

C. 37 CFR §1.97(d). Although this Information Disclosure Statement is being filed after the mailing date of the earlier of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, it is being filed before payment of the issue fee and should be considered because it is accompanied by:

i. a statement as specified in §1.97(e);

-- AND --

ii. a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.

D. 37 CFR §1.97(e). Statement.

A statement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);

-- AND/OR --

A statement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);

-- AND/OR --

A copy of a dated communication from a foreign patent office clearly showing that the information disclosure statement is being submitted within 3 months of the filing date on the communication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as provided for under MPEP 609.04(b) V.

E. *Statement Under 37 C.F.R. §1.704(d).* Each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart application that was received by an individual designated in § 1.56(c) not more than thirty (30) days prior to the filing of this information disclosure statement. This statement is made pursuant to the requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term for Applicant(s) delay.

F. *37 CFR §1.98(a)(2).* The content of the Information Disclosure Statement is as follows:

Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.

-- OR --

Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.

-- AND/OR --

Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).

-- AND/OR --

Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).

G. *37 CFR §1.98(a)(3).* The Information Disclosure Statement includes non-English patents and/or references.

Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.

Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.

-- OR --

A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows: _____

Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.

H. *37 CFR §1.98(d).* Copies of patents, publications and pending U.S. patent applications, or other information specified in 37 C.F.R. § 1.98(a) are not provided herewith because:

Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.

Application in which the information was submitted: _____

Information Disclosure Statement(s) filed on: _____

AND

The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

I. *Fee Authorization.* The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.28450-703.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: 12/14/06

By: 
Jeffrey W. Glise
Reg. No. 84,613

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 021971

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	09/942,959	
Sheet	1	Of	1	Filing Date	August 31, 2002	
				First Named Inventor	Robert S. Osbakken	
				Art Unit	1614	
				Examiner Name	Donna Jagoe	
				Attorney Docket Number		28450-703.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
1.	US-4,950,477		08-21-1990	Schmitt et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* - Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
2.	DE-19925289		12-07-2000	Hexal AG		✓
3.	EP-499344		08-19-1992	RikerLab Inc.		
4.	GB-2,338,649		12-29-1999	Hawtin BF		
5.	WO-1998-13001		04-02-1998	Nastech Pharm. Co.		
6.	WO-1999-22703		05-14-1999	Lurident Ltd.		
7.	WO-2000-10528		03-02-2000	Procter & Gamble		
8.	WO-2000-10529		03-02-2000	Procter & Gamble		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
9.	AURORA, J., "Development of Nasal Delivery Systems: A Review," Drug Delivery Technology 2(7): 8 pages (October 2002), http://www.drugdelivery.com/cgi-bin/articles.cgi?idArticle=85 (accessed 06/15/04)		
10.	BOMMER, R., "Latest Advances in Nasal Drug-Delivery Technology," Medical Device Technology 10(4):22-28 (1999)		
11.	KUBLIK et al., "Nasal delivery system and their effect on deposition and absorption,: Advanced Drug Delivery Reviews 29:157-177 (1998)		

Examiner Signature	Date Considered

*EXAMINER: List all references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of each reference considered, unless applicant's application is for a design patent or a utility model application. *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 501.06. *Notes: Office that issued the document, by whom the kind code was assigned (e.g., Japanese patent documents, do not use the kind code of the Japanese Patent Office, use the serial number of the issued document). *Kind of document by the appropriate symbols as indicated on the document under "WIPO Standard ST.16" if possible. (Applicant is to place a check mark here if English language Translation is attached.)

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, may be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.